Lyell Immunopharma, Inc. (LYEL) — Cash & Equivalents
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $60.18M | -43.0% |
| 2024 | $105.60M | -27.5% |
| 2023 | $145.65M | +17.9% |
| 2022 | $123.55M | -58.0% |
| 2021 | $293.83M | +109.3% |
| 2020 | $140.41M | +45.2% |
| 2019 | $96.67M | — |
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $60.18M | -43.0% |
| 2024 | $105.60M | -27.5% |
| 2023 | $145.65M | +17.9% |
| 2022 | $123.55M | -58.0% |
| 2021 | $293.83M | +109.3% |
| 2020 | $140.41M | +45.2% |
| 2019 | $96.67M | — |